Preclinical development of T cell receptor gene therapy

Gavin M Bendle; John B A G Haanen; Ton N M Schumacher

doi:10.1016/j.coi.2009.02.007

Preclinical development of T cell receptor gene therapy

Gavin M Bendle, John B A G Haanen, Ton N M Schumacher

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

Abstract

The adoptive transfer of TCR gene-modified T cells has been developed with the aim to induce immune reactivity toward defined tumor-associated antigens to which the endogenous T cell repertoire is non-responsive. Here we discuss in which areas preclinical studies in mouse models can or cannot be expected to be of value to guide clinical trial design, and how the available data from preclinical studies should influence forthcoming clinical trials.

Original language	English
Pages (from-to)	209-14
Number of pages	6
Journal	Current Opinion in Immunology
Volume	21
Issue number	2
DOIs	https://doi.org/10.1016/j.coi.2009.02.007
Publication status	Published - Apr 2009

Access to Document

10.1016/j.coi.2009.02.007

Cite this

@article{eb8e3b6bb1644a149d128f6f06d923f3,

title = "Preclinical development of T cell receptor gene therapy",

abstract = "The adoptive transfer of TCR gene-modified T cells has been developed with the aim to induce immune reactivity toward defined tumor-associated antigens to which the endogenous T cell repertoire is non-responsive. Here we discuss in which areas preclinical studies in mouse models can or cannot be expected to be of value to guide clinical trial design, and how the available data from preclinical studies should influence forthcoming clinical trials.",

author = "Bendle, {Gavin M} and Haanen, {John B A G} and Schumacher, {Ton N M}",

year = "2009",

month = apr,

doi = "10.1016/j.coi.2009.02.007",

language = "English",

volume = "21",

pages = "209--14",

journal = "Current Opinion in Immunology",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Preclinical development of T cell receptor gene therapy

AU - Bendle, Gavin M

AU - Haanen, John B A G

AU - Schumacher, Ton N M

PY - 2009/4

Y1 - 2009/4

N2 - The adoptive transfer of TCR gene-modified T cells has been developed with the aim to induce immune reactivity toward defined tumor-associated antigens to which the endogenous T cell repertoire is non-responsive. Here we discuss in which areas preclinical studies in mouse models can or cannot be expected to be of value to guide clinical trial design, and how the available data from preclinical studies should influence forthcoming clinical trials.

AB - The adoptive transfer of TCR gene-modified T cells has been developed with the aim to induce immune reactivity toward defined tumor-associated antigens to which the endogenous T cell repertoire is non-responsive. Here we discuss in which areas preclinical studies in mouse models can or cannot be expected to be of value to guide clinical trial design, and how the available data from preclinical studies should influence forthcoming clinical trials.

U2 - 10.1016/j.coi.2009.02.007

DO - 10.1016/j.coi.2009.02.007

M3 - Article

C2 - 19321326

VL - 21

SP - 209

EP - 214

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

IS - 2

ER -

Preclinical development of T cell receptor gene therapy

Abstract

Access to Document

Fingerprint

Cite this